Ligand Pharmaceuticals reported $67.67M in Cash and Equivalent for its fiscal quarter ending in June of 2025.


Cash And Equivalent Change Date
Amgen USD 8.03B 782M Jun/2025
Arrowhead Research USD 129.79M 55.92M Jun/2025
Baxter International USD 2.29B 530M Mar/2025
Bristol-Myers Squibb USD 12.6B 1.72B Jun/2025
Eli Lilly USD 3.38B 282.6M Jun/2025
Gilead Sciences USD 5.14B 2.78B Jun/2025
GlaxoSmithKline GBP 3.6B 865M Jun/2025
Glaxosmithkline GBP 3.6B 271M Jun/2025
Insmed USD 1.28B 881.08M Jun/2025
Ionis Pharmaceuticals USD 297.3M 33.11M Jun/2025
Ligand Pharmaceuticals USD 67.67M 189.22M Jun/2025
MacroGenics USD 130.69M 52.15M Jun/2025
Merck USD 8.01B 622M Jun/2025
Pacira USD 300.48M 16.87M Jun/2025
Pfizer USD 1.64B 208M Jun/2025
Veracyte USD 219.5M 33.38M Jun/2025